<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169815</url>
  </required_header>
  <id_info>
    <org_study_id>HF-01-19</org_study_id>
    <nct_id>NCT04169815</nct_id>
  </id_info>
  <brief_title>Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection</brief_title>
  <official_title>Pivotal Evaluation of the Access Natriuretic Peptdie Assay(s) as an Aid in the Diagnosis and Assessment of Severity of Acute Heart Failure - Emergency Department Subject Enrollment and Specimen Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the pivotal study is to collect blood specimens and clinical data from
      patients suspected of having Heart Failure (HF), which will be tested at a future date on
      Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective clinical sample collection and future natriuretic peptide testing will be
      conducted in an emergency department only population. Patients presenting to the Emergency
      Department (ED) with signs and symptoms of acute heart failure will be approached for
      enrollment.

      Clinical and laboratory data will be collected to establish product performance and clinical
      concordance to adjudicated clinical diagnosis. Approximately 1800 evaluable subjects at
      geographically dispersed sites in the US will be enrolled in the study.

      Sample collection and testing of clinical samples with the Access Natriuretic Peptide assay
      will be performed under two separate protocols
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of the future Natriuretic Peptide Assay(s)</measure>
    <time_frame>Single blood draw upon study entry at day 1</time_frame>
    <description>Establish the performance of the future Natriuretic Peptide assay(s) against the adjudicated diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Severity Assessment</measure>
    <time_frame>Single blood draw upon study entry at day 1 and two remote follow up visits</time_frame>
    <description>Demonstrate that the Access Natriuretic Peptide Assay may be used for assessment of heart failure severity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>ED Setting</arm_group_label>
    <description>An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access Immunodiagnostic Products</intervention_name>
    <description>Access Natriuretic Peptide Assay</description>
    <arm_group_label>ED Setting</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population will be representative of an acute heart failure population enrolled at
        Emergency Departments. Patients presenting with a suspicion of acute heart failure will be
        approached for enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent obtained

          -  Adult aged 21 years or older

          -  Presenting with a clinical suspicion of acute HF

          -  Subject clinical history available for review by Sponsor or delegates and FDA or other
             regulatory agencies

        Exclusion Criteria:

          -  Dyspnea clearly not secondary to HF (e.g. primary lung disease or chest trauma)

          -  Stage 4 or 5 Chronic Kidney Disease (CKD)

          -  Chronic dialysis

          -  Participation in a clinical study that may interfere with participation in this study

          -  Anything that would place the individual at increased risk or preclude the
             individual's full compliance with or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erika Bladholm</last_name>
    <phone>952-368-7714</phone>
    <email>elbladholm@beckman.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Director Clinical Affairs</last_name>
    <phone>952-368-7714</phone>
    <email>dharkness@beckman.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beckman Coulter Site AB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beckman Coulter Site AA</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006 Feb 21;47(4):742-8. Epub 2006 Jan 26.</citation>
    <PMID>16487838</PMID>
  </reference>
  <reference>
    <citation>Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993 May;132(5):1961-70.</citation>
    <PMID>8477647</PMID>
  </reference>
  <reference>
    <citation>Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005 May;91(5):606-12.</citation>
    <PMID>15831643</PMID>
  </reference>
  <reference>
    <citation>Friedewald VE Jr, Burnett JC Jr, Januzzi JL Jr, Roberts WC, Yancy CW. The editor's roundtable: B-type natriuretic peptide. Am J Cardiol. 2008 Jun 15;101(12):1733-40. doi: 10.1016/j.amjcard.2008.03.017. Epub 2008 Apr 22. Review.</citation>
    <PMID>18549849</PMID>
  </reference>
  <reference>
    <citation>O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140. doi: 10.1016/j.jacc.2012.11.019. Epub 2012 Dec 17.</citation>
    <PMID>23256914</PMID>
  </reference>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz√°lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.</citation>
    <PMID>27207191</PMID>
  </reference>
  <reference>
    <citation>Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb;27(3):330-7. Epub 2005 Nov 17.</citation>
    <PMID>16293638</PMID>
  </reference>
  <reference>
    <citation>Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul 18;347(3):161-7.</citation>
    <PMID>12124404</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natriuretic Peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

